CARNEXIV (carbamazepine) by Lundbeck is mechanism of action carbamazepine has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. First approved in 2016.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
CARNEXIV is an intravenous formulation of carbamazepine, a small-molecule anticonvulsant approved in 2016 by Lundbeck. It reduces polysynaptic responses and blocks post-tetanic potentiation to control seizures and neuropathic pain. The drug's mechanism remains incompletely understood, though its active metabolite carbamazepine-10,11-epoxide contributes to anticonvulsant activity.
Product is at peak lifecycle stage with no reported competitive pressure, suggesting stable revenue and a mature but focused commercial team.
Mechanism of Action Carbamazepine has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Carbamazepine greatly reduces or abolishes pain induced…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
Worked on CARNEXIV at Lundbeck? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moCARNEXIV is a niche specialty IV product with limited public job postings, indicating a lean, focused commercial team at Lundbeck. Career opportunities are concentrated in brand management, field specialty sales, and medical affairs roles supporting a stable, mature product.